{"Antibodies": [0], "targeting": [1], "programmed": [2], "cell": [3], "death": [4], "protein-1": [5], "(PD-1)": [6], "or": [7, 138, 151], "its": [8], "ligand": [9], "PD-L1": [10], "rescue": [11], "T": [12], "cells": [13], "from": [14], "exhausted": [15], "status": [16], "and": [17, 43, 45, 51, 88, 145, 176, 191, 218, 232], "revive": [18], "immune": [19, 96, 120], "response": [20, 64, 97, 147], "against": [21], "cancer": [22, 75, 219], "cells.": [23], "Based": [24], "on": [25, 203], "the": [26, 62, 81, 125, 187, 204, 214, 226], "immense": [27], "success": [28], "in": [29, 170, 195, 210], "clinical": [30, 211], "trials,": [31], "ten": [32], "\u03b1-PD-1": [33], "(nivolumab,": [34], "pembrolizumab,": [35], "cemiplimab,": [36], "sintilimab,": [37], "camrelizumab,": [38], "toripalimab,": [39], "tislelizumab,": [40], "zimberelimab,": [41], "prolgolimab,": [42], "dostarlimab)": [44], "three": [46], "\u03b1-PD-L1": [47], "antibodies": [48, 153], "(atezolizumab,": [49], "durvalumab,": [50], "avelumab)": [52], "have": [53, 141], "been": [54, 104], "approved": [55], "for": [56], "various": [57], "types": [58], "of": [59, 66, 85, 124, 129, 193, 206, 228], "cancers.": [60], "Nevertheless,": [61], "low": [63], "rate": [65], "\u03b1-PD-1/PD-L1": [67, 111, 155, 194], "therapy": [68], "remains": [69], "to": [70, 92], "be": [71], "resolved.": [72], "For": [73], "most": [74], "patients,": [76], "PD-1/PD-L1": [77, 100], "pathway": [78], "is": [79, 90], "not": [80], "sole": [82], "speed-limiting": [83], "factor": [84], "antitumor": [86, 95, 143, 161, 189], "immunity,": [87], "it": [89], "insufficient": [91], "motivate": [93], "effective": [94], "by": [98], "blocking": [99], "axis.": [101], "It": [102], "has": [103], "validated": [105], "that": [106], "some": [107], "combination": [108, 164, 196, 222], "therapies,": [109], "including": [110], "plus": [112], "chemotherapy,": [113], "radiotherapy,": [114], "angiogenesis": [115], "inhibitors,": [116, 122], "targeted": [117], "therapy,": [118], "other": [119, 198], "checkpoint": [121], "agonists": [123], "co-stimulatory": [126], "molecule,": [127], "stimulator": [128], "interferon": [130], "genes": [131], "agonists,": [132], "fecal": [133], "microbiota": [134], "transplantation,": [135], "epigenetic": [136], "modulators,": [137, 140], "metabolic": [139], "superior": [142], "efficacies": [144, 190], "higher": [146], "rates.": [148], "Moreover,": [149, 200], "bifunctional": [150], "bispecific": [152], "containing": [154], "moiety": [156], "also": [157], "elicited": [158], "more": [159], "potent": [160], "activity.": [162], "These": [163], "strategies": [165, 209, 231], "simultaneously": [166], "boost": [167], "multiple": [168], "processes": [169], "cancer-immunity": [171], "cycle,": [172], "remove": [173], "immunosuppressive": [174], "brakes,": [175], "orchestrate": [177], "an": [178], "immunosupportive": [179], "tumor": [180], "microenvironment.": [181], "In": [182], "this": [183], "review,": [184], "we": [185, 201], "summarized": [186], "synergistic": [188], "mechanisms": [192], "with": [197], "therapies.": [199], "focused": [202], "advances": [205], "\u03b1-PD-1/PD-L1-based": [207, 229], "immunomodulatory": [208, 230], "studies.": [212], "Given": [213], "heterogeneity": [215], "across": [216], "patients": [217], "types,": [220], "individualized": [221], "selection": [223], "could": [224], "improve": [225], "effects": [227], "relieve": [233], "treatment": [234], "resistance.": [235]}